Corporate News

Inhibikase Therapeutics (IKT) Faces a Decline in Market Value While Peers Experience Mixed Performance

In the trading session that concluded at 12:39 PM Central Europe on Thursday, 22 November 2026, Inhibikase Therapeutics (IKT) registered a decline of 2.92 %. The share price settled at approximately USD 1.66 on major exchanges. With a current supply of 182.1 million shares, the company’s market capitalisation stands at USD 311.4 million. In the last 24 hours, roughly USD 878.1 k of IKT shares were traded.

Historical Context

Over the past month, IKT’s share price has fallen by 28.14 %. The simple moving average of the last 200 days is USD 1.94. The 52‑week high, achieved on 3 September 2026, was USD 2.61, while the 52‑week low, recorded on 3 November 2025, was USD 1.33.

Peer Performance in the Last 24 Hours

  • Zura Bio (ZURA) Trade: Up 3.25 %Price: USD 4.13Market Cap: USD 371.8 million

  • Viemed Healthcare (VMD) Trade: Down 0.51 %Price: USD 9.75Market Cap: USD 373.3 millionP/E Ratio: 27.09

  • LendingTree, Inc. (TREE) Trade: Up 0.19 %Price: USD 26.58Market Cap: USD 372.5 millionP/E Ratio: 2.11Upcoming Events: LendingTree will announce its fiscal third‑quarter 2026 earnings after the market close on 3 November 2026. A shareholder letter will be published on its investor website, followed by an earnings conference call at 4:30 p.m. ET. The call will be webcast and subsequently made available for replay. The company highlighted its role as a major player in the digital financial services sector, emphasizing its commitment to providing consumers with tailored financial options and tools through the LendingTree.com marketplace.

  • Norwood (NWFL) Trade: Down 0.62 %Price: USD 33.7Market Cap: USD 367.7 millionP/E Ratio: 11.79

  • Kyverna Therapeutics (KYTX) Trade: Down 3.31 %Price: USD 5.84Market Cap: USD 373.5 millionRecent Announcement: Kyverna disclosed the complete one‑year data set from its Phase 2 registrational study of miv‑cel in patients with stiff person syndrome. The results indicated a modest increase in the median improvement in the timed 25‑foot walk from the primary‑endpoint time point to one year. A large proportion of participants achieved clinically meaningful gains across secondary measures of disability, mobility, stiffness, and sensitivity. Most patients remained free from chronic immunotherapies. Safety data remained favorable, with no severe cytokine‑release or neurotoxicity events, and only manageable low‑grade neutropenia and resolved serious adverse events. The company emphasized the sustained benefit and tolerability of a single dose, suggesting a potential shift in the treatment paradigm for the disease.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. is a clinical‑stage pharmaceutical company headquartered in Atlanta, United States. The company specializes in developing and commercializing small‑molecule kinase inhibitor therapeutics aimed at safely and effectively treating neurodegeneration, both within and outside the brain.